Cann Group (ASX:CAN) is Australia’s first commercially licensed medicinal cannabis cultivator and manufacturer. We supply PIC/S GMP certified, high-THC dried flower as both API and finished product, and a range of extracts and oral oils, to our B2B customers in Australia, Germany and the UK. And our patented micro-encapsulated CBD capsules, currently undergoing Phase III clinical trials, are available throughout the world under the Satipharm brand.

The first stage of our new, state-of-the-art facility in regional Victoria is fully operational, with in-house analytical chemistry and microbiology laboratories, and the capacity to produce 12,500kg of high-quality flower per year, with subsequent stages planned in response to growing demand. We have extensive R&D collaborations with globally renowned agricultural and pharmaceutical research partners, and have developed our own exclusive, proprietary lines of high-yielding cultivars.

Cann Group is committed to the future of high-quality, low-cost cannabis medicines, and the development of a reliable and trusted industry.